Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy
1 competing product in clinical development for Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy.
Pipeline by Phase
Phase 31
All Products (1)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimen | Sun Pharmaceutical | Phase 3 | UNKNOWN | 36 |